Answers are grounded in this paper and cite their sources.
Background: Metabolic syndrome (MetS) has become a global health challenge with several associated issues, such as obesity, insulin resistance, dyslipidemia, and hypertension. Important proteins such as Tumor Necrosis Factor-alpha (TNF-α) and Hypoxia Inducible Factor-2 alpha (HIF-2α) regulate the inflammatory process by inducing the expression of pro-inflammatory proteins. Secretome Hypoxia Mesenchymal Stem Cells (SH-MSCs) are immunomodulatory, anti-inflammatory, and angiogenic stimulators, which can regulate various inflammatory diseases, including MetS. Objective: This study aims to determine the effect of administering SH-MSCSs on the expression of the TNF-α and Hypoxia Inducible Factor (HIF)-2α genes in the male Wistar rat model with Metabolic Syndrome. Method: This research is an experimental study with a Post-test Only Control Group Design, using a total of 24 male Wistar rats divided into four groups: T1 (Healthy control), T2 (MetS + NaCl), T3 (MetS + administration of SH-MSCs dose 150 uL), and T4 (MetS + administration of SH-MSCs dose 300 uL). SH-MSCSs were administered intraperitoneally four times over 14 days. Adipose tissue TNF-α and HIF-2α gene expression were measured on day 15 using qRT-PCR. Results: TNF-α and HIF-2α gene expression was significantly lower in T3 and T4, compared with the MetS control group (T2). Conclusion: Administration of SH-MSCs was able to reduce the expression of the Tumor Necrosis Factor (TNF-α) and Hypoxia Inducible Factor (HIF)-2α genes in fatty tissue in the male Wistar rat model with Metabolic Syndrome.
No takes yet. Share an insight, caveat, or question.
Dewi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: